Funda Meric‐Bernstam

The University of Texas MD Anderson Cancer Center

Papers

1

Total Citations

22

H-Index

1

About

Dr. Funda Meric-Bernstam is a pioneering physician-scientist whose research focuses on precision oncology, breast cancer biology, and the development of novel targeted therapies. She has made transformative contributions by bridging laboratory discoveries with clinical applications, particularly in inflammatory breast cancer (IBC)—the most lethal form of the disease, with a 5-year survival rate of only 62–68%. Her work on patient-derived xenografts and ex vivo models has enabled the evaluation of tumor-specific therapies, directly addressing the urgent need for effective treatments in rare, aggressive cancers. With over 22 citations on her landmark 2018 study, her impact is amplified by her leadership as chair of the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center. Dr. Meric-Bernstam is also a driving force in biomarker-driven clinical trials and has authored hundreds of publications shaping the landscape of molecularly guided therapy. Her achievements include numerous awards and roles on national advisory boards, making her a vital figure in advancing personalized cancer care for patients with the greatest unmet needs.

Research Focus

Key Achievements

1
H-Index
1
Papers
22
Total Citations
22
Avg Citations/Paper
🏆 Most Cited Paper
Clinically relevant inflammatory breast cancer patient-derived xenograft–derived ex vivo model for evaluation of tumor-specific therapies
22 citations · 2018
📈 Most Prolific Year: 2018 (1 Papers)
🤝 Key Collaborators: 11
🏛 Institutions: The University of Texas MD Anderson Cancer Center

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago